000309924 001__ 309924
000309924 005__ 20260219142831.0
000309924 0247_ $$2doi$$a10.1007/s00117-026-01573-y
000309924 0247_ $$2pmid$$apmid:41703060
000309924 0247_ $$2ISSN$$a2731-7048
000309924 0247_ $$2ISSN$$a0033-832X
000309924 0247_ $$2ISSN$$a1432-2102
000309924 0247_ $$2ISSN$$a2731-7056
000309924 037__ $$aDKFZ-2026-00374
000309924 041__ $$aGerman
000309924 082__ $$a610
000309924 1001_ $$0P:(DE-HGF)0$$aFendler, Wolfgang P$$b0
000309924 245__ $$aPositronen-Emissions-Tomographie bei Sarkomen.
000309924 260__ $$a[Berlin]$$bSpringer Medizin Verlag GmbH$$c2026
000309924 3367_ $$2DRIVER$$aarticle
000309924 3367_ $$2DataCite$$aOutput Types/Journal article
000309924 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771507698_3004206$$xReview Article
000309924 3367_ $$2BibTeX$$aARTICLE
000309924 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309924 3367_ $$00$$2EndNote$$aJournal Article
000309924 500__ $$a#DKTKZFB9# / #NCTZFB9# / epub
000309924 520__ $$aSarcomas are rare, heterogeneous tumors of mesenchymal origin. Molecular imaging is crucial for diagnosis, staging, and therapy monitoring. 18F‑Fluorodeoxyglucose (18F‑FDG) positron-emission tomography/computed tomography (PET/CT) is a powerful technique for imaging high-grade soft tissue and bone sarcomas and supports staging, grading, biopsy targeting, and risk assessment using standardized criteria, e.g., European Organization for Treatment of Cancer (EORTC) criteria and PET Response Criteria in Solid Tumors (PERCIST).Fibroblast activation protein (FAP) is expressed at high concentrations in many sarcomas, often directly on the tumor cells themselves as well as on cancer-associated fibroblasts. FAP is therefore an attractive target for molecular imaging and therapy. 68Ga-labeled FAP inhibitors (FAPIs) have shown higher uptake compared to 18F‑FDG across all sarcoma subtypes, including those with low 18F‑FDG avidity. FAPI-PET shows favorable tumor-background contrast and strong correlation with histopathological FAP expression. Prospective studies suggest that FAPI-PET may be superior to 18F‑FDG-PET in certain histological subtypes and may identify candidates for FAP-targeted radioligand therapy (RLT). Early clinical experience with radioligands such as 90Y‑FAPI-46 demonstrates safety, feasibility, and disease control under FAP-RLT in more than half of evaluable patients with advanced metastatic sarcoma.Further prospective studies are needed to evaluate and establish the role of 18F‑FDG and FAPI-PET in personalized treatment strategies and sarcoma management.
000309924 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000309924 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309924 650_7 $$2Other$$aFibroblast activation protein
000309924 650_7 $$2Other$$aMolecular imaging
000309924 650_7 $$2Other$$aRadioligand therapy
000309924 650_7 $$2Other$$aRare tumors
000309924 650_7 $$2Other$$aStandardized uptake value
000309924 7001_ $$0P:(DE-HGF)0$$aKessler, Lukas$$b1
000309924 7001_ $$0P:(DE-HGF)0$$aHimmen, Stephan$$b2
000309924 7001_ $$aHamacher, Rainer$$b3
000309924 773__ $$0PERI:(DE-600)3120921-X$$a10.1007/s00117-026-01573-y$$pnn$$tDie Radiologie$$vnn$$x2731-7048$$y2026
000309924 909CO $$ooai:inrepo02.dkfz.de:309924$$pVDB
000309924 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000309924 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000309924 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000309924 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000309924 9141_ $$y2026
000309924 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-12$$wger
000309924 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-12$$wger
000309924 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOLOGIE : 2022$$d2025-11-12
000309924 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-12
000309924 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-12
000309924 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-12
000309924 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-12
000309924 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-12
000309924 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-12
000309924 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-12
000309924 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-11-12
000309924 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000309924 9201_ $$0I:(DE-He78)WT01-20160331$$kWT01$$lKoordinierungsstelle NCT West$$x1
000309924 980__ $$ajournal
000309924 980__ $$aVDB
000309924 980__ $$aI:(DE-He78)ED01-20160331
000309924 980__ $$aI:(DE-He78)WT01-20160331
000309924 980__ $$aUNRESTRICTED